118 related articles for article (PubMed ID: 9068770)
21. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
[TBL] [Abstract][Full Text] [Related]
22. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.
Vandel P; Haffen E; Vandel S; Bonin B; Nezelof S; Sechter D; Broly F; Bizouard P; Dalery J
Eur J Clin Pharmacol; 1999 Nov; 55(9):659-65. PubMed ID: 10638395
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.
Inada T; Senoo H; Iijima Y; Yamauchi T; Yagi G
Psychiatr Genet; 2003 Sep; 13(3):163-8. PubMed ID: 12960748
[TBL] [Abstract][Full Text] [Related]
24. The association between CYP2D6 genotype and switching antipsychotic medication to clozapine.
Gregoor JG; van der Weide K; van der Weide J; van Megen HJ; Egberts AC; Heerdink ER
Eur J Clin Pharmacol; 2013 Nov; 69(11):1927-32. PubMed ID: 23831869
[TBL] [Abstract][Full Text] [Related]
25. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.
Patsopoulos NA; Ntzani EE; Zintzaras E; Ioannidis JP
Pharmacogenet Genomics; 2005 Mar; 15(3):151-8. PubMed ID: 15861039
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
27. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.
Schillevoort I; de Boer A; van der Weide J; Steijns LS; Roos RA; Jansen PA; Leufkens HG
Pharmacogenetics; 2002 Apr; 12(3):235-40. PubMed ID: 11927839
[TBL] [Abstract][Full Text] [Related]
28. [Acute dyskinetic syndrome during chloropromazine treatment of a female patient with CYP2D6 poor metabolism phenotype].
Beszłej JA; Grzesiak M; Milejski P
Psychiatr Pol; 2007; 41(4):495-501. PubMed ID: 18046980
[TBL] [Abstract][Full Text] [Related]
29. CYP2D6 and GSTM1 genotypes in a Polish population.
Gawronska-Szklarz B; Wójcicki M; Kuprianowicz A; Kedzierska K; Kedzierski M; Górnik W; Pawlik A
Eur J Clin Pharmacol; 1999 Jul; 55(5):389-92. PubMed ID: 10456489
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome P4502D6 genotype does not determine response to clozapine.
Arranz MJ; Dawson E; Shaikh S; Sham P; Sharma T; Aitchison K; Crocq MA; Gill M; Kerwin R; Collier DA
Br J Clin Pharmacol; 1995 Apr; 39(4):417-20. PubMed ID: 7640149
[TBL] [Abstract][Full Text] [Related]
31. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
Dorado P; Peñas-Lledó EM; Llerena A
Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
[TBL] [Abstract][Full Text] [Related]
32. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial.
Jürgens G; Andersen SE; Rasmussen HB; Werge T; Jensen HD; Kaas-Hansen BS; Nordentoft M
JAMA Netw Open; 2020 Dec; 3(12):e2027909. PubMed ID: 33284338
[TBL] [Abstract][Full Text] [Related]
33. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
34. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
35. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
[TBL] [Abstract][Full Text] [Related]
36. Liver enzyme
Lu JY; Tiwari AK; Freeman N; Zai GC; Luca V; Müller DJ; Tampakeras M; Herbert D; Emmerson H; Cheema SY; King N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL; Zai CC
Pharmacogenomics; 2020 Oct; 21(15):1065-1072. PubMed ID: 32969762
[No Abstract] [Full Text] [Related]
37. Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.
Mannheimer B; Holm J; Koukel L; Bertilsson L; Osby U; Eliasson E
Eur J Clin Pharmacol; 2014 Jun; 70(6):695-9. PubMed ID: 24643635
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
Dahl ML
Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
[TBL] [Abstract][Full Text] [Related]
40. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.
Arthur H; Dahl ML; Siwers B; Sjöqvist F
J Clin Psychopharmacol; 1995 Jun; 15(3):211-6. PubMed ID: 7635999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]